logo
Why AI Transformation Is Non-Negotiable For Executives

Why AI Transformation Is Non-Negotiable For Executives

Forbes7 hours ago
Greg Genung is CEO and founder of Snowfire AI, a pioneer in AI signals and decision intelligence technology.
There are two types of executives in this new era of AI. The first is an executive who's still using antiquated systems to run their business, mainly on intuition. The second is an executive running an AI-transformed business, fully leveraging automation and real-time intelligent analyses that augment their intuition.
There's a massive shift happening in the executive layer in companies worldwide. And based on my industry experience, I've found that a delay in AI transformation is a dangerous game. So, to help support executives in overcoming their unpreparedness, I built an AI transformation ROI formula that helps determine the financial impact of AI implementation—or, looking at it another way, the cost of inaction. This formula offers a way for C-suite executives, private equity or venture capital managers, portfolio companies and founders to measure AI's impact and take steps to help improve growth, margins and retention in the age of AI.
The Stakes: What You Lose By Waiting
Inaction is a death spiral. Competitors wielding AI are capturing markets, slashing costs and securing customer loyalty while you're mired in outdated systems. CEOs sometimes see AI as a threat to their positions. A Dataiku and Harris Poll survey shows that 74% of CEOs globally said "they could lose their job within two years if they don't deliver measurable AI-driven business gains." No one escapes this transformation. Executives and employees are all aware that AI is disrupting their roles.
This isn't just a skills gap; it's a mindset problem that stalls progress and inflates costs as inefficiencies mount. The transformational impact that AI is having across the C-suite is creating quite a bit of discomfort for executives. Our data shows that only 15% of organizations say their C-suite has high AI proficiency. This is a red flag when nearly 30% believe the CEO's role will be the one most transformed by AI. Without executive fluency in AI and the role it plays in business transformation, businesses risk missteps that cede ground to rivals. Hesitation costs money.
The ATI ROI Formula: How To Measure AI's Transformative Power
To quantify what's at stake, I developed a return on investment (ROI) formula to determine how AI platforms can impact the entire business—the AI transformation impact (ATI) formula:
AI transformation impact = (Revenue Growth * Margin Improvement * Retention %) / (Total Headcount / AI Efficiency %).
In short form: ATI = (RGI * MEF * CRF) / (HC / AEF)
RGI: Revenue And Growth Index = TR * (1 + % Revenue Growth) * (1 + % Market Expansion)
MEF: Margin Efficiency Factor = 1 + (% Gross Margin Improvement - % COGS Increase)
CRF: Customer Retention Factor = 1 + (% Retention Rate Improvement - % Churn Increase)
HC: Headcount (e.g., 100 employees)
AEF: AI Efficiency Factor = 1 + % Productivity Gain
Example: A company with $10 million in revenue and 100 employees adopts AI, achieving 20% revenue growth, 10% market expansion, 15% margin improvement, 5% COGS (cost of goods sold) increase, 10% retention improvement, 2% churn increase and 30% productivity gain. RGI = $13.2 million, MEF = 1.1, CRF = 1.08 and adjusted headcount = 100 / 1.3 ≈ 76.92. ATI = ($13.2M * 1.1 * 1.08) / 76.92 ≈ $203,923, dwarfing the pre-AI performance of $100,000 per employee.
Delay AI, and you're stuck at the lower figure, hemorrhaging millions to competitors. This formula reveals what inaction sacrifices: revenue, margins, growth and loyalty.
The Risks Of Delay
For executives, the burden of inaction is personal and punishing. CEOs face relentless board pressure to deliver growth, but without AI, they're blindsided by market shifts, eroding their credibility as missed opportunities pile up. Across the C-suite, inaction means longer hours, tougher scrutiny and the constant threat of being outmaneuvered. The research underscores the following key areas of focus for executives:
• C-Suite Knowledge Gap: With only 15% of organizations reporting high C-suite AI proficiency in our survey, executives are ill-equipped to lead transformation. This gap risks strategic missteps, like the competitor who ignored AI market analysis and lost 10% revenue.
• Data Integration Gaps: AI demands unified data from CRM and ERP systems, marketing, the supply chain and support teams. Gartner researchers estimate that, through 2026, 60% of AI projects will be unfinished due to poor data.
• Rising Costs: Inaction compounds inefficiencies, inflating COGS and delaying ROI. Manual processes drain budgets while rivals optimize.
Urgent Steps To Act Now
From my experience and research, here are critical steps to take to avoid costly inaction:
• Unify data immediately. Integrate CRM (sales), ERP (financials), marketing (customer insights), supply chain (operations) and support (retention) data to power AI. A client unified these to spot demand trends, boosting margins by 12%. Delay risks silos that cost revenue—start mapping data today.
• Launch a pilot. Test AI in one area, like pricing for CFOs. A client's finance team gained 10% margins in three months. Waiting cedes profits to competitors.
• Upskill the C-suite. Invest in executive AI training—15% proficiency is a liability.
• Set up governance. Form an AI ethics committee to prevent bias and build trust. Late governance cost one firm a key client due to flawed AI pricing.
Inaction Risks Irrelevance
The cost of inaction can be devastating. For executives wary of numbers, it's simple: AI means selling more (new markets), keeping more (higher profits) and holding customers close (less churn), with your team working smarter. One of our client's 40% value surge came from acting fast—unifying data, piloting AI and training their team. Their competitor's delay likely cost millions.
Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Guggenheim Raises GeneDx (WGS) Price Target, Maintaining a Buy Rating
Guggenheim Raises GeneDx (WGS) Price Target, Maintaining a Buy Rating

Yahoo

time11 minutes ago

  • Yahoo

Guggenheim Raises GeneDx (WGS) Price Target, Maintaining a Buy Rating

GeneDx Holdings Corp (NASDAQ:WGS) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Guggenheim analyst Subbu Nambi has raised the price target for GeneDx Holdings Corp (NASDAQ:WGS) from $88.00 to $115.00, reinforcing a bullish stance on the company's long-term trajectory. The 'Buy' rating remains unchanged, signaling confidence in GeneDx's market position and its potential to capture a growing share of the precision medicine space. A modern office space where the team is engaging in business development and management services. GeneDx, known for its deep expertise in rare disease genomics and next-generation sequencing, is emerging as a leader in healthcare innovation. The company blends advanced bioinformatics with clinical expertise to help physicians diagnose complex, genetically driven conditions more efficiently. Its platform leverages massive datasets and machine learning algorithms to interpret whole-genome and exome sequencing, placing it squarely in the center of the healthcare AI movement. The price target hike reflects Guggenheim's view that GeneDx is well-positioned to benefit from the increasing demand for personalized medicine and the broader integration of data-driven tools in clinical care. As health systems and biopharma partners seek faster, more accurate diagnostic solutions, GeneDx's technology and scalable infrastructure make it a critical player in the shift toward AI-enabled healthcare. With momentum building across both clinical and commercial channels, the company appears to be gaining traction at a pivotal time for genomic medicine. The revised valuation underscores growing investor recognition of GeneDx's role in transforming how rare and complex diseases are diagnosed and managed. While we acknowledge the potential of WGS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than WGS and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now. Disclosure: None. Sign in to access your portfolio

Morgan Stanley Raises iRhythm (IRTC) Price Target, Maintains Overweight Rating
Morgan Stanley Raises iRhythm (IRTC) Price Target, Maintains Overweight Rating

Yahoo

time11 minutes ago

  • Yahoo

Morgan Stanley Raises iRhythm (IRTC) Price Target, Maintains Overweight Rating

iRhythm Technologies, Inc. (NASDAQ:IRTC) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Morgan Stanley has raised its price target on iRhythm Technologies, Inc. (NASDAQ:IRTC) to $160 from $130, while maintaining an 'Overweight' rating, citing strong early indicators for the company's second-quarter performance. In a recent note to investors, the firm pointed to a surge in MyZio app downloads, which totaled 171,169 in Q2—up 74% year-over-year and 36% compared to the first quarter. The increase suggests iRhythm may outperform Street estimates, as most of the Zio patches generating revenue for the quarter have already been prescribed and tied to active monitoring. A patient being monitored with a portable ECG device, showing the effectiveness of the company's products. Morgan Stanley highlighted that the strong app adoption signals growing patient engagement and broader acceptance of digital cardiac care, which bodes well for both short- and long-term growth. With scalable infrastructure and a rising volume of clinical data feeding its algorithms, iRhythm is not only improving detection but also redefining remote patient monitoring. As healthcare shifts toward personalized, tech-driven models, iRhythm's innovation and execution place it among the leaders in digital diagnostics. Morgan Stanley views the company as a compelling investment amid increasing demand for smart, connected health solutions. iRhythm Technologies, Inc. (NASDAQ:IRTC) develops and markets the Zio platform, a patch-based cardiac monitoring solution that leverages advanced analytics and machine learning to detect arrhythmias with clinical-grade accuracy. The company's AI-enabled technology analyzes millions of heartbeats in real time, helping physicians diagnose conditions like atrial fibrillation more effectively than traditional methods. While we acknowledge the potential of IRTC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IRTC and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now. Disclosure: None. Sign in to access your portfolio

Schrödinger (SDGR) Receives FDA Fast Track Designation for Cancer Drug SGR-1505
Schrödinger (SDGR) Receives FDA Fast Track Designation for Cancer Drug SGR-1505

Yahoo

time11 minutes ago

  • Yahoo

Schrödinger (SDGR) Receives FDA Fast Track Designation for Cancer Drug SGR-1505

Schrödinger, Inc. (NASDAQ:SDGR) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Schrödinger, Inc. (NASDAQ:SDGR) announced that its investigational drug SGR-1505 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of adults with Waldenström macroglobulinemia who have not responded to at least two prior therapies, including a Bruton's tyrosine kinase (BTK) inhibitor. The designation is designed to expedite the development and review of drugs that address serious or life-threatening conditions with unmet medical need. A biopharmaceutical executive discussing plans with a government laboratory. SGR-1505 is a selective MALT1 inhibitor currently in clinical development. Waldenström macroglobulinemia is a rare type of non-Hodgkin lymphoma, and treatment-resistant forms present significant challenges for patients and clinicians. Schrödinger's approach to drug discovery gives it a unique advantage in targeting such difficult diseases. The company is best known for its computational platform that integrates physics-based modeling and advanced algorithms to design novel compounds with greater precision and efficiency. This model-driven strategy makes Schrödinger one of the few healthcare companies at the forefront of computational drug discovery—a field that blends molecular science with cutting-edge software to identify and optimize potential therapies faster than traditional methods. With the FDA's Fast Track status, SGR-1505 may benefit from more frequent interaction with the agency and potential eligibility for accelerated approval, positioning Schrödinger to advance an important treatment option while reinforcing its growing role as a technology-driven innovator in the pharmaceutical sector. While we acknowledge the potential of SDGR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SDGR and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store